Compounds and compositions for modulating egfr mutant kinase activities

A compound of Formula (I):

• wherein:
• X is CH or N;
• R1 is H, R8 or —OR8;
• R2 is hydrogen, C1-6 alkyl, 6-10 membered monocyclic or bicyclic aryl, or 5-10 membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R13;
• and wherein the heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R8;
• R3 is hydrogen, 4-7 membered monocyclic heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, and optionally substituted with oxo, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, NR9R10, NR11R12, or phenyl, wherein the heteroaryl or phenyl is optionally and independently substituted at one or more carbon atoms with R13;
• and wherein the heterocyclyl or heteroaryl having one or more nitrogen atoms is optionally and independently substituted at one or more nitrogen atoms with R8;
• R4 is hydrogen, C1-4 alkyl, C3-5 cycloalkyl, F, Cl, Br, CN, or CF3;
• R5 is hydrogen, CF3, C1-6 alkyl, C3-7 cycloalkyl, 5-6 membered heteroaryl comprising 1-3 heteroatoms selected from N, O and S, or 6-10 membered monocyclic or bicyclic aryl, wherein the heteroaryl or aryl is optionally and independently substituted at one or more carbon atoms with R13;
• R6 is hydrogen or C1-6 alkyl;
• R7 is hydrogen, —CH2OH, —CH2OR8, C1-3 alkyl, (CH2)nNR9R10, (CH2)nNR11R12, C(O)NR9R10, or C(O)NR11R12, wherein each n is independently 1 or 2;
• R8 is selected from C1-6 alkyl or C3-7 cycloalkyl;
• R9 is selected from C1-6 alkyl, C3-7 cycloalkyl or 4-7 membered heterocyclyl comprising 1-2 heteroatoms selected from N, O and S, wherein the C1-6 alkyl or C3-7 cycloalkyl is optionally substituted with halogen or —OR8, and wherein the 4-7 membered heterocyclyl having one nitrogen atom is optionally and independently substituted with —R8, —C(O)R8, —C(O)OR8, or C(O)NHR8;
• R10 is C1-6 alkyl, C3-7 cycloalkyl, or (CH2)nNR9R9, wherein each n is independently 1 or 2;
• R11 and R12, taken together with nitrogen atom to which they are bonded form, independently for each occurrence,
• i) a 3-8 membered saturated or partially saturated monocyclic group having no heteroatom other than the nitrogen atom to which R11 and R12 are bonded, wherein said 3-8 membered saturated or partially saturated monocyclic group is optionally and independently substituted at one or more carbons with halogen, hydroxyl, —OR8, —NR9R10, or —NR11R12;
• or
• ii) a 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 heteroatoms, in addition to the nitrogen atom to which R11 and R12 are bonded, wherein said heteroatoms are independently selected from nitrogen, oxygen, sulfur, sulfone or sulfoxide, wherein said 5-8 membered saturated or partially saturated monocyclic group having 1 or 2 nitrogen atoms is optionally substituted at one or more carbon or nitrogen atoms with —R8, —C(O)R8, —C(O)OR8, —C(O)NHR8, —SO2R8, —SO2NH2, or —SO2NR82;
• and
• R13 is selected from halogen, CN, CF3, R8, —OR8 or C2-4 alkenyl,
• or a pharmaceutically acceptable salt thereof.